Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age

Alexander Armstrong; Huong Ho; Mark Tacey; Damien Bolton; Yee Chan; Alwin Tan; Chee Wee Cham; Trung Pham; Kevin McMillan; George Koufogiannis; Paul Manohar; Mario Guerrieri; Michael Ng; Daryl Lim Joon; Farshad Foroudi; Mun Yee Tan; Michael Chao

doi:10.5114/jcb.2024.135630

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

1/2024
vol. 16

Send email

Copy url:

abstract:

Original paper

Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age

Alexander Armstrong

¹

,

Huong Ho

²

,

Mark Tacey

^{3, 4}

,

Damien Bolton

⁵

,

Yee Chan

⁶

,

Alwin Tan

⁷

,

Chee Wee Cham

⁷

,

Trung Pham

⁸

,

Kevin McMillan

⁹

,

George Koufogiannis

¹⁰

,

Paul Manohar

¹¹

,

Mario Guerrieri

¹²

,

Michael Ng

¹²

,

Daryl Lim Joon

¹³

,

Farshad Foroudi

¹³

,

Mun Yee Tan

¹⁴

,

Michael Chao

^{12, 13}

Department of Radiation Oncology, North Coast Cancer Institute, Lismore Cancer Care and Hematology Unit, Lismore, NSW, Australia

GenesisCare Ringwood Vic., Australia

Department of Radiation Oncology, Austin Health, Heidelberg, Australia

Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia

Department of Surgery, Austin Health, Heidelberg, Vic., Australia

Department of Surgery, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Vic., Australia

The Bays Hospital, Mornington, Vic., Australia

Mulgrave Private Hospital, Mulgrave, Vic., Australia

Box Hill Hospital, Box Hill, Vic., Australia

10.

Ringwood Private Hospital, Ringwood East, Vic., Australia

11.

St John of God Specialist Centre, Berwick, Vic., Australia

12.

Genesis Cancer Care Victoria, Melbourne, Australia

13.

Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Vic., Australia

14.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia

J Contemp Brachytherapy 2024; 16, 1: 6–11

DOI: https://doi.org/10.5114/jcb.2024.135630

Online publish date: 2024/02/23

View full text Get citation

Purpose:
Low-dose-rate (LDR) brachytherapy in young men remains controversial amongst urologists due to their concerns regarding long-term biochemical control and treatment-related toxicities. The purpose of this study was to evaluate the treatment outcomes of men under 60 years of age who underwent LDR brachytherapy with iodine-125 (¹²⁵I) for clinically localized low- to intermediate-risk prostate cancer.

Material and methods:
All consecutive patients with clinically localized prostate cancer treated at our institution from 2003 to 2016 with ¹²⁵I monotherapy were included in the study. Prescription dose was 145.0 Gy modified peripheral loading (MPD). All patients were assessed for biochemical progression-free survival using Phoenix definition (nadir +2 ng/ml), clinical progression-free survival, overall survival (OS), and any associated treatment toxicity.

Results:
A total of 161 patients were included, with a median follow-up of 6.8 years (range, 3-14.54 years). Median age at implant was 57 years (range, 53-59 years). Mean prostate specific antigen (PSA) level at diagnosis was 4.43 ng/ml (SD = 2.29). Majority of men had low-risk prostate cancer (70.2%). Biochemical progression-free survival at 8 years was 94% for the entire cohort. Median PSA at 4 years was 0.169 (IQR, 0.096-0.360), with 45% of patients having a PSA greater than 0.2. OS was 96.9%, with 5 deaths reported but only one was secondary to prostate cancer. Late grade > 2 genitourinary toxicities were reported in 18 patients (11.2%). Three patients (1.9%) developed secondary cancers, all considered unrelated to their LDR brachytherapy.

Conclusions:
With excellent long-term treatment outcomes and minimal associated toxicities, our results showed that LDR brachytherapy can be an effective treatment of choice in younger men.

keywords:

Low-dose-rate brachytherapy and long-term treatment outcomes in patients younger than 60 years of age

prostate cancer, brachytherapy, toxicity, low-dose-rate, long-term treatment outcomes